Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Enterprise value

Enterprise value at other companies

AbbVie logo
AbbVieABBV
$460.96B+24.7%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$2.27B-4.1%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$8.56B+52.9%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$13.41B+18.5%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$16.37B+47.7%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$3.56B+36.6%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Calculated from Supernus Pharmaceuticals’s reported figures.

$3.0Bmarket cap+$40.9Mtotal debt−$186.3Mcash and equivalents=$2.83B

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's enterprise value?
Supernus Pharmaceuticals (SUPN) reported enterprise value of $2.83B in Q1 2026.
How has Supernus Pharmaceuticals's enterprise value changed year-over-year?
Supernus Pharmaceuticals's enterprise value increased by 62.3% year-over-year, from $1.74B to $2.83B.
What is the long-term trend for Supernus Pharmaceuticals's enterprise value?
Over 5 years (2020 to 2025), Supernus Pharmaceuticals's enterprise value has grown at a 20.1% compound annual growth rate (CAGR), from $1.1B to $2.76B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.